Status:
UNKNOWN
The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23
Lead Sponsor:
Camillians Saint Mary's Hospital Luodong
Conditions:
Other Nonspecific Abnormal Serum Enzyme Levels
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To compare the effect of lanthanum carbonate with calcium carbonate on serum FGF23 levels in hemodialysis patients.
Detailed Description
The investigators enrolled patients on maintenance hemodialysis and randomized them to two groups. One group will receive lanthanum carbonate and another group will receive calcium carbonate. The inve...
Eligibility Criteria
Inclusion
- Age \> 18 years old
- Chronic renal failure on maintenance hemodialysis 3 times a week for at least 3 months Serum calcium:8-10.5 mg/dL
- Serum phosphate:3.5-6 mg/dL(before washout period)
- Serum phosphate ≧6 mg/dL after washout period
- Serum i-PTH: 150-600 pg/mL
Exclusion
- Diabetes mellitus
- Post parathyroidectomy
- Life expectancy\< 6 months
- Liver disease(hepatitis B,C or liver dysfunction)
- Severe gastrointestinal disorders or other severe comorbidity
- Poor compliance
- Intolerance to lanthanum or calcium carbonate
- Active infection
- Malnutrition(serum albumin\<3 g/dL or clinical assessment)
- Kt/V\< 1.2 (inadequate dialysis)
- Serum phosphate\>7.5 mg/dL after washout period
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01845090
Start Date
August 1 2011
End Date
July 1 2014
Last Update
May 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Mary's hospital-Lotung
Taipei, Taiwan, 265